24.89  2.03 (8.88%)		05-11 12:25
Open: 23.2 High: 26 Volume: 166,191		Pre. Close: 22.86 Low: 23.2 Market Cap: 345(M)

Short term
Mid term
Targets	6-month :	31.21	1-year :	35.34
Resists	First :	26.72	Second :	30.26
Pivot price	23.35
Supports	First :	21	Second :	17.47
MAs	MA(5) :	23.37	MA(20) :	24.07
	MA(100) :	24.46	MA(250) :	15.89
MACD	MACD :	-0.5	Signal :	-0.6
%K %D	K(14,3) :	42.3	D(3) :	28
RSI	RSI(14): 53.5
52-week	High :	34.09	Low :	7.78

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GLSI ] has closed below upper band by 5.8%. Bollinger Bands are 59.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	23.91 - 24.04	24.04 - 24.13
Low:	22.58 - 22.71	22.71 - 22.8
Close:	22.66 - 22.87	22.87 - 23.03

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Thu, 30 Apr 2026
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan

Thu, 30 Apr 2026
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - ChartMill

Thu, 23 Apr 2026
Breast cancer immunotherapy study lands ASCO 2026 poster slot - Stock Titan

Wed, 22 Apr 2026
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - GlobeNewswire

Wed, 22 Apr 2026
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan

Mon, 20 Apr 2026
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	14 (M)
Shares Float	7 (M)
Held by Insiders	50.7 (%)
Held by Institutions	11 (%)
Shares Short	1,520 (K)
Shares Short P.Month	1,420 (K)

EPS	-1.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.15
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-254.2 %
Return on Equity (ttm)	-543.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.42
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	-1 (M)

PE Ratio	-17.16
PEG Ratio	0
Price to Book value	156.56
Price to Sales	0
Price to Cash Flow	-40.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.